维生素D补充与死亡率的相关性:系统综述与Meta分析
该系统综述与Meta分析纳入52项随机对照试验、共75454名参与者,比较维生素D补充与安慰剂或不治疗对死亡率的影响。维生素D补充与全因死亡率、心血管死亡率及非癌症非心血管死亡率均无显著关联,但使癌症死亡风险降低16%。亚组分析中维生素D3试验的全因死亡率显著低于维生素D2试验(交互作用P=0.04),但维生素D3和维生素D2单独均与全因死亡率无统计学显著降低。
要点
- 52项随机对照试验共75454人,维生素D补充与全因死亡率无显著关联(RR 0.98,95%CI 0.95至1.02)。
- 维生素D补充使癌症死亡风险降低16%(RR 0.84,95%CI 0.74至0.95)。
- 维生素D3试验的全因死亡率显著低于维生素D2试验(交互作用P=0.04)。
核心结论
- 与安慰剂或不治疗相比,成人单独补充维生素D与全因死亡率无显著关联。
- 维生素D补充使癌症死亡风险降低16%。
- 需要更多大型临床研究来确定维生素D3补充是否与较低的全因死亡率相关。
研究设计与样本
- 系统综述与随机对照试验的Meta分析,检索Medline、Embase和Cochrane Central Register从建库至2018年12月26日的文献。
- 纳入比较维生素D补充与安慰剂或不治疗对死亡率影响的随机对照试验,共纳入52项试验、75454名参与者。
- 采用固定效应和随机效应模型计算维生素D补充组与对照组的死亡风险比。
主要发现
- 维生素D补充与全因死亡率无显著关联(风险比0.98,95%置信区间0.95至1.02,I²=0%)。
- 维生素D补充与心血管死亡率无显著关联(风险比0.98,95%置信区间0.88至1.08,I²=0%)。
- 维生素D补充与非癌症非心血管死亡率无显著关联(风险比1.05,95%置信区间0.93至1.18,I²=0%)。
- 维生素D补充使癌症死亡风险显著降低(风险比0.84,95%置信区间0.74至0.95,I²=0%)。
- 亚组分析中,维生素D3补充试验的全因死亡率显著低于维生素D2补充试验(交互作用P=0.04);维生素D3和维生素D2单独均与全因死亡率无统计学显著降低。
关键数值与推荐
- 全因死亡率:风险比0.98(95%置信区间0.95至1.02,I²=0%)。
- 心血管死亡率:风险比0.98(95%置信区间0.88至1.08,I²=0%)。
- 非癌症非心血管死亡率:风险比1.05(95%置信区间0.93至1.18,I²=0%)。
- 癌症死亡率:风险比0.84(95%置信区间0.74至0.95,I²=0%)。
- 维生素D3与维生素D2试验全因死亡率交互作用P=0.04。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多大型临床研究来确定维生素D3补充是否与较低的全因死亡率相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether vitamin D supplementation is associated with lower mortality in adults. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Central Register from their inception to 26 December 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing vitamin D supplementation with a placebo or no treatment for mortality were included. Independent data extraction was conducted and study quality assessed. A meta-analysis was carried out by using fixed effects and random effects models to calculate risk ratio of death in the group receiving vitamin D supplementation and the control group. MAIN OUTCOME MEASURES: All cause mortality. RESULTS: 52 trials with a total of 75 454 participants were identified. Vitamin D supplementation was not associated with all cause mortality (risk ratio 0.98, 95% confidence interval 0.95 to 1.02, I2=0%), cardiovascular mortality (0.98, 0.88 to 1.08, 0%), or non-cancer, non-cardiovascular mortality (1.05, 0.93 to 1.18, 0%). Vitamin D supplementation statistically significantly reduced the risk of cancer death (0.84, 0.74 to 0.95, 0%). In subgroup analyses, all cause mortality was significantly lower in trials with vitamin D3 supplementation than in trials with vitamin D2 supplementation (P for interaction=0.04); neither vitamin D3 nor vitamin D2 was associated with a statistically significant reduction in all cause mortality. CONCLUSIONS: Vitamin D supplementation alone was not associated with all cause mortality in adults compared with placebo or no treatment. Vitamin D supplementation reduced the risk of cancer death by 16%. Additional large clinical studies are needed to determine whether vitamin D3 supplementation is associated with lower all cause mortality. STUDY REGISTRATION: PROSPERO registration number CRD42018117823.
引用
- Zhang Y, Fang F, Tang J, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019. PMID: 31405892. doi:10.1136/bmj.l4673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。